

<b>Title</b>	Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML
<b>Author(s)</b>	Moloney, Jennifer N.; Jayavelu, Ashok Kumar; Stanicka, Joanna; Roche, Sarah L.; O'Brien, Rebecca L.; Scholl, Sebastian; Boehmer, Frank-D.; Cotter, Thomas G.
<b>Publication date</b>	2017
<b>Original citation</b>	Moloney, J. N., Jayavelu, A. K., Stanicka, J., Roche, S. L., O'Brien, R. L., Scholl, S., Böhmer, F.-D. and Cotter, T. G. (2017) 'Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML', <i>Oncotarget</i> , 8(62), pp. 105440-105457. doi: 10.18632/oncotarget.22241
<b>Type of publication</b>	Article (peer-reviewed)
<b>Link to publisher's version</b>	<a href="http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path[]=22241&amp;path[]=70409">http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path[]=22241&amp;path[]=70409</a> <a href="http://dx.doi.org/10.18632/oncotarget.22241">http://dx.doi.org/10.18632/oncotarget.22241</a> Access to the full text of the published version may require a subscription.
<b>Rights</b>	© 2017, Moloney et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. <a href="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</a>
<b>Item downloaded from</b>	<a href="http://hdl.handle.net/10468/6339">http://hdl.handle.net/10468/6339</a>

Downloaded on 2019-01-07T05:57:38Z

# Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML

Jennifer N. Moloney<sup>1</sup>, Ashok Kumar Jayavelu<sup>2,3</sup>, Joanna Stanicka<sup>1</sup>, Sarah L. Roche<sup>1</sup>, Rebecca L. O'Brien<sup>1</sup>, Sebastian Scholl<sup>4</sup>, Frank-D. Böhmer<sup>2</sup> and Thomas G. Cotter<sup>1</sup>

<sup>1</sup>Tumour Biology Laboratory, School of Biochemistry and Cell Biology, Bioscience Research Institute, University College Cork, Cork, Ireland

<sup>2</sup>Institute of Molecular Cell Biology, CMB, Jena University Hospital, Jena, Germany

<sup>3</sup>Current address: Department of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany

<sup>4</sup>Department of Haematology/Oncology, Clinic for Internal Medicine II, Jena University Hospital, Jena, Germany

**Correspondence to:** Thomas G. Cotter, **email:** t.cotter@ucc.ie

**Keywords:** acute myeloid leukaemia; FLT3-ITD; pro-survival reactive oxygen species; NOX4 splice variant D/NOX4D 28 kDa; nuclear membrane

**Received:** July 27, 2017

**Accepted:** October 02, 2017

**Published:** November 01, 2017

**Copyright:** Moloney et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

**Internal tandem duplication of the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3-ITD) is the most prevalent genetic aberration present in 20-30% of acute myeloid leukaemia (AML) cases and is associated with a poor prognosis. FLT3-ITD expressing cells express elevated levels of NADPH oxidase 4 (NOX4)-generated pro-survival hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) contributing to increased levels of DNA oxidation and double strand breaks. NOX4 is constitutively active and has been found to have various isoforms expressed at multiple locations within a cell. The purpose of this study was to investigate the expression, localisation and regulation of NOX4 28 kDa splice variant, NOX4D. NOX4D has previously been shown to localise to the nucleus and nucleolus in various cell types and is implicated in the generation of reactive oxygen species (ROS) and DNA damage. Here, we demonstrate that FLT3-ITD expressing-AML patient samples as well as -cell lines express the NOX4D isoform resulting in elevated H<sub>2</sub>O<sub>2</sub> levels compared to FLT3-WT expressing cells, as quantified by flow cytometry. Cell fractionation indicated that NOX4D is nuclear membrane-localised in FLT3-ITD expressing cells. Treatment of MV4-11 cells with receptor trafficking inhibitors, tunicamycin and brefeldin A, resulted in deglycosylation of NOX4 and NOX4D. Inhibition of the FLT3 receptor revealed that the FLT3-ITD oncogene is responsible for the production of NOX4D-generated H<sub>2</sub>O<sub>2</sub> in AML. We found that inhibition of the PI3K/AKT and STAT5 pathways resulted in down-regulation of NOX4D-generated pro-survival ROS. Taken together these findings indicate that nuclear membrane-localised NOX4D-generated pro-survival H<sub>2</sub>O<sub>2</sub> may be contributing to genetic instability in FLT3-ITD expressing AML.**

## INTRODUCTION

Aberrant signalling of receptor tyrosine kinases (RTKs) is associated with tumour development and transformation [1-3]. FMS-like tyrosine kinase 3 (FLT3)

is a type III RTK expressed in approximately 90% of acute myeloid leukaemia (AML) and plays a critical role in normal haematopoiesis [4-6]. Internal tandem duplication (ITD) of sequences in the juxtamembrane domain is the most prevalent genetic aberration of FLT3, with a gain of

function mutation, implicated in 20-30% of AML patients [5, 7-10]. Patients with this mutation have a particularly poor prognosis with a high incidence of relapse [11-13]. Constitutive activation of the tyrosine kinase domain of FLT3-ITD results in autophosphorylation and activation of downstream pro-survival cascades including PI3K/AKT, ERK1/2 and STAT5 resulting in the promotion of cell survival, proliferation and transformation in myeloid leukaemia [9, 10, 14-19]. It has been demonstrated that AML cells expressing the FLT3-ITD mutation produce higher levels of reactive oxygen species (ROS) and DNA damage compared to their wild-type counterpart [20-23].

ROS have been long implicated in leukaemia cancer pathology due to their ability to induce DNA damage [24, 25]. The NADPH oxidase (NOX) family consisting of NOX1-5 and dual oxidase (DUOX) 1 and 2, are well established producers of ROS [26], with NOX2 and NOX4 playing a central role in the increased production of hydrogen peroxide ( $H_2O_2$ ) in AML [23, 27, 28]. NOX proteins vary in structure, subcellular localisation, biochemical characteristics and regulatory subunits (p22<sup>phox</sup>, p47<sup>phox</sup>, p67<sup>phox</sup> and Rac1/2). p22 phagocyte oxidase (p22<sup>phox</sup>) is a partner protein and is required for functionally active NOX1-4 [29-31]. Among the NOX family members NOX4 is unique. It is constitutively activated, generating  $H_2O_2$ , unlike its family members NOX1 and NOX2, which require an agonist for activation [32-34]. Oxidation of protein tyrosine phosphatases (PTPs) occurs in FLT3-ITD expressing AML cells. NOX4-driven ROS formation causes partial inactivation of DEP-1/PTPRJ, a transmembrane PTP responsible for negative regulation of FLT3 signalling, contributing to unfavourable downstream signalling [27].

NOX4 subcellular localisation plays an important role, given its constitutive activity. NOX4 has been reported to be expressed in the cytoskeleton [35], endoplasmic reticulum (ER) [30, 36-38], mitochondria [39, 40], plasma membrane [38, 41] and nucleus [42-44] in different cell types. Previous studies in our laboratory have shown that NOX4 and p22<sup>phox</sup> co-localise to the nuclear membrane by immunofluorescence in FLT3-ITD expressing MV4-11 AML cell line contributing to DNA oxidation and double strand breaks (dsbs), possibly driving genetic instability [23].

Previous studies identified NOX4 isoforms, expressed at varying levels, in the presence of the prototype in the human lung cancer cell line, A549 cells. The truncated NOX4 splice variant D (28 kDa) lacks the majority of the transmembrane domain and has been shown to produce higher levels of ROS and DNA damage compared to its prototype [45]. NOX4D retains the NADPH and FAD-binding domains required for electron transfer activity and ROS production despite its truncation [46]. NOX4D is localised to the nucleus and nucleolus in vascular smooth muscle cells (VSMC), A7R5 cells and in many other cells including human aortic vascular smooth muscle cells,

human umbilical vein endothelium cells (HUVEC), H9C2 rat cardiomyocytes, human embryonic kidney fibroblasts (HEK), mouse primary cardiac fibroblasts and rat neonatal cardiomyocytes. NOX4D is expected to be soluble rather than membrane-localised [42].

To investigate if FLT3-ITD expressing AML cells express NOX4D and in order to identify the localisation of NOX4D we utilised subcellular fractionation, inhibitors of FLT3-ITD and pro-survival signalling pathways, siRNA, alongside ROS specific probes and antibodies. Experiments were carried out in *de novo* primary AML samples, human patient-derived AML cell line MV4-11 and in the murine haematopoietic 32D cell lines stably harbouring FLT3-wild type (FLT3-WT) receptor and FLT3-ITD mutation.

We show that FLT3-ITD expressing AML patient samples and cell lines express the NOX4D 28 kDa splice variant. FLT3-ITD expressing AML cells express NOX4D in the nuclear membrane, which may be contributing to genetic instability in AML. NOX4D expression is dependent on the FLT3-ITD mutation. NOX4 partner protein p22<sup>phox</sup> does not regulate NOX4 or NOX4D protein expression. Inhibition of the PI3K and STAT5 pro-survival pathways results in decreased expression of NOX4D alongside a decrease in endogenous  $H_2O_2$  detected using the  $H_2O_2$  specific probe Peroxy Orange 1 (PO1). Inhibition of ERK1/2 signalling had no effect on NOX4D protein expression, however a decrease in p22<sup>phox</sup> protein levels alongside a decrease in endogenous  $H_2O_2$  was observed. Inhibition of GSK3 $\beta$  resulted in increased expression of NOX4 and NOX4D, however, a slight decrease in endogenous  $H_2O_2$  was observed. This demonstrates that NOX4D is downstream of FLT3-ITD signalling in AML, located in the nuclear membrane where it may be contributing to DNA damage and disease progression.

## RESULTS

### FLT3-ITD expressing AML patient samples, MV4-11 and 32D/FLT3-ITD cells express the NOX4 splice variant NOX4D 28 kDa in the nuclear membrane

FLT3-ITD expressing AML cells have been shown previously to express higher levels of total endogenous  $H_2O_2$ , DNA oxidation and dsbs compared to FLT3-WT cells [8, 23]. NOX4 has been well established as a producer of pro-survival ROS in FLT3-ITD expressing AML, contributing to DNA damage and disease progression [23, 27]. As mentioned previously, NOX4 is unique to other members of the NOX family of proteins in its constitutive activation. Therefore, NOX4 subcellular localisation plays an important role in cellular regulation. Our group has previously shown that NOX4 and p22<sup>phox</sup> co-localise to the nuclear membrane in MV4-11 cells [23]. Previous studies identified the presence of NOX4 isoforms, including NOX4 splice variant NOX4D (28 kDa), to be

expressed and localised to the nucleus and nucleolus of VSMC where it is contributing to ROS production, DNA damage and genetic instability [42]. We investigated if FLT3-ITD- and FLT3-WT-expressing AML patient samples expressed the NOX4D isoform and also examined the expression and localisation of NOX4D 28 kDa in two cell lines: FLT3-ITD-expressing AML MV4-11 cell line and 32D cell line stably transfected with FLT3-WT or FLT3-ITD. Localisation of NOX4D was assessed by means of subcellular fractionation. We show that NOX4D is expressed in FLT3-ITD expressing patient samples and cells, but is absent in FLT3-WT patient samples and 32D cells transfected with the FLT3-WT receptor (Figure 1A-1C). NOX4D is localised to the membrane and soluble nuclear fractions of MV4-11 cells (Figure 1B) and the membrane, soluble nuclear and chromatin bound nuclear (chr.b.nuclear) fractions of 32D cells stably transfected with FLT3-ITD (Figure 1C). In support of previous work, we have identified the NOX4 prototype (67 kDa) in the soluble nuclear fraction and p22<sup>phox</sup> in the membrane and soluble nuclear fractions in both MV4-11 cells (Figure 1B) and 32D/FLT3-ITD cells (Figure 1C). Interestingly, we found NOX4 67 kDa was lacking from the membrane fraction in MV4-11 cells (Figure 1B). In contrast NOX4 67 kDa was observed in the membrane fraction of 32D/FLT3-ITD cells (Figure 1C). There are therefore clear differences in NOX4 67 kDa subcellular localisation between these cell lines.

### Specificity of NOX4 antibodies

Studies have raised issues with NOX4 antibody specificity in the past, due to difficulties in detecting NOX4 protein expression. Therefore, a key issue concerned the use of the Abcam NOX4 antibody (Ab109225) and the Novus Biologicals NOX4 antibody (NB110-58849) in our study. For this reason, a series of control experiments were first performed to validate the NOX4 antibodies employed in this study.

To validate the specificity of the Abcam NOX4 antibody (Ab109225) against NOX4 67 kDa and NOX4D 28 kDa in primary AML samples in this study, NOX4 knockdowns were carried out in 32D/FLT3-ITD cells. Specific NOX4 knockdowns using NOX4 targeted siRNA and shRNA in 32D/FLT3-ITD cells resulted in depletion of NOX4 67 kDa protein levels detected using Abcam NOX4 antibody (Supplementary Figure 1A). The remainder of the experiments in this study employed the Novus Biologicals NOX4 antibody (NB110-58849). In order to demonstrate specificity of this antibody for NOX4 67 kDa and NOX4D 28 kDa, HEK-293-T cells were transfected with empty vector (EV)-HA or p-CMV3-C-HA encoding NOX4 and were analysed 48 h post transfection by western blot. NOX4 overexpression in HEK 293-T cells resulted in increased NOX4 67 kDa and NOX4D 28 kDa protein expression in the presence of HA protein expression at the corresponding molecular weights compared to HEK 293-T cells transfected

with EV (Supplementary Figure 1B). Together, these experiments validated that the NOX4 antibodies used in this study were specific for NOX4 67 kDa and NOX4D 28 kDa.

### 32D cells stably transfected with FLT3-ITD express higher levels of endogenous H<sub>2</sub>O<sub>2</sub> compared to FLT3-WT

FLT3-ITD expressing AML cells have been shown to produce elevated levels of ROS and DNA damage compared to their wild type counterpart [23]. Having confirmed that FLT3-ITD expressing AML patient samples and 32D cells express NOX4D whereas FLT3-WT expressing patient samples and 32D cells do not, we investigated the effect of NOX4D expression on total endogenous H<sub>2</sub>O<sub>2</sub>. We demonstrate that 32D cells stably transfected with FLT3-ITD produced ~170% more endogenous H<sub>2</sub>O<sub>2</sub> than 32D cells stably transfected with FLT3-WT receptor, as assessed with a H<sub>2</sub>O<sub>2</sub> specific probe-PO1 (Figure 1D).

### p22<sup>phox</sup> knockdown had no effect on NOX4 67 kDa and NOX4D 28 kDa protein levels

p22<sup>phox</sup> is a partner protein and is required for functionally active NOX1-4 [30]. Specific p22<sup>phox</sup> knockdown allowed us to investigate the effects of p22<sup>phox</sup> on NOX4 67 kDa and NOX4D 28 kDa protein expression. Knockdown of p22<sup>phox</sup> had no effect on NOX4 67 kDa and NOX4D 28 kDa protein levels (Figure 2A).

### Inhibition of glycosylation in MV4-11 cell line resulted in NOX4 67 kDa and NOX4D 28 kDa deglycosylation


Previous studies in our laboratory have found NOX4 67 kDa to be glycosylated in FLT3-ITD expressing AML MV4-11 cells [28]. We investigated if NOX4D 28 kDa is glycosylated in the MV4-11 cell line. Cells were treated with glycosylation inhibitor, tunicamycin and receptor trafficking inhibitor, brefeldin A. Treatment of MV4-11 cells with glycosylation and receptor trafficking inhibitors resulted in deglycosylation of NOX4D 28 kDa as seen by the presence of a lower molecular weight band marked by asterisks (Figure 2B).

### Inhibition of FLT3-ITD in MV4-11 cell line and 32D cells transfected with FLT3-ITD causes a decrease in NOX4 67 kDa and NOX4D 28 kDa protein levels as well as reductions in total endogenous H<sub>2</sub>O<sub>2</sub>

32D cells transfected with FLT3-ITD and FLT3-WT receptor along with MV4-11 cells were treated with FLT3-ITD inhibitor, PKC412. The inhibition of FLT3 receptor resulted in a decrease in total endogenous H<sub>2</sub>O<sub>2</sub>

in 32D/FLT3-ITD cells, but not in 32D/FLT3-WT cells. As shown previously in Figure 1D 32D/FLT3-ITD cells

possess ~170% more total endogenous H<sub>2</sub>O<sub>2</sub> compared to their wild-type counterpart. Moreover, inhibition of




**Figure 1: FLT3-ITD expressing AML patient samples and cell lines express the NOX4D 28 kDa isoform.** (A) Western blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein expression in FLT3-ITD- and FLT3-WT-expressing AML patient samples.  $\beta$ -actin and Vinculin were used as loading controls. (B and C) Subcellular fractionation was carried out in FLT3-ITD expressing AML cell line, MV4-11 (B) and 32D cells transfected with FLT3-WT or FLT3-ITD (C). Expression of NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> was assessed by means of western blot analysis. Equal loading of samples and verification of the subcellular fractions were demonstrated by probing for nuclear-localised NUP98, HDAC1 and Histone H3, membrane-localised calreticulin and KDEL and cytosolic-localised GAPDH. Blots are representative of five independent experiments. (D) (i) 32D cells stably transfected with FLT3-WT and FLT3-ITD were IL-3 starved overnight, followed by ROS visualisation with H<sub>2</sub>O<sub>2</sub> specific probe, Peroxy Orange 1 (PO1) for 1 h before flow cytometric analysis. (ii) Bar chart shows relative mean PO1 fluorescence of 32D/FLT3-ITD cells expressed as a % of 32D/FLT3-WT cells. The results are representative of three independent experiments. Asterisks indicate statistically significant differences (\*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars represent SD.

FLT3 resulted in ~40% decrease in total endogenous H<sub>2</sub>O<sub>2</sub> following treatment with 50 nM and 200 nM PKC412 specifically in 32D cells expressing the FLT3-ITD mutation and not in cells expressing FLT3-WT receptor (Figure 3A). FLT3-ITD expressing MV4-11 cells were treated with PKC412. Inhibition of the FLT3 receptor in MV4-11 cells resulted in decreased NOX4 67 kDa and NOX4D 28 kDa protein levels in whole cell lysates (Figure 3B) and reduced total endogenous H<sub>2</sub>O<sub>2</sub>. 50 nM and 200 nM PKC412 treatments resulted in a decrease of 45-50% in total endogenous H<sub>2</sub>O<sub>2</sub> (Figure 3C). The inhibition of FLT3-ITD using AC220, another commonly used and very selective FLT3 receptor inhibitor, resulted in decreased NOX4D 28 kDa protein levels in the nuclear fractions of MV4-11 cells (Figure 3D) and 32D/FLT3-ITD cells (Figure 3E). In Figure 3D and 3E, Lamin A/C is used as a marker for nuclear fractions. Lamin A/C is cleaved by caspase-6 and serves as a marker of caspase-6 activation. During apoptosis, Lamin A/C is specifically cleaved to a large (40-45 kDa) and a small (28 kDa) fragment. The cleavage of Lamin A/C results in nuclear dysregulation and death. These results suggest that both FLT3-ITD and NOX4D proteins play a role in the generation of H<sub>2</sub>O<sub>2</sub> in MV4-11 and 32D/FLT3-ITD cells and that FLT3-ITD activity is presumably an upstream regulator of NOX4D-generated pro-survival ROS.

### PI3K/AKT pathway is required for FLT3-ITD mediated-NOX4 67 kDa and -NOX4D 28 kDa generation of pro-survival H<sub>2</sub>O<sub>2</sub>

Constitutively activated FLT3-ITD kinase stimulates aberrant proliferative signalling through downstream signalling pathways including PI3K/AKT, ERK1/2, STAT5 and GSK3β. We have shown previously that NOX4- and p22<sup>phox</sup>-generated pro-survival ROS require AKT activation in MV4-11 cells [28]. Therefore, we examined the effect of PI3K/AKT inhibition on NOX4D 28 kDa protein expression in membrane and soluble nuclear fractions of MV4-11 cells. Inhibition of AKT (Figure 4A) using PI3K inhibitor LY294002 resulted in slight decreases in NOX4 67 kDa protein expression and more noticeable decreases in NOX4D 28 kDa and p22<sup>phox</sup> protein expression in the soluble nuclear fraction (Figure 4B). As shown, NOX4D 28 kDa protein expression is weak in the membrane fraction and it is therefore difficult to detect any change. We next examined the effect of AKT inhibition on the generation of total endogenous H<sub>2</sub>O<sub>2</sub>. AKT inhibition resulted in ~25% decrease in total endogenous H<sub>2</sub>O<sub>2</sub> following treatment with 20 μM and 30 μM LY294002 and ~35% decrease following treatment with 50 μM LY294002 (Figure 4C). Thus, activation of the AKT pathway is required for FLT3-ITD to produce NOX4D-generated ROS.




**Figure 2: Knockdown of p22<sup>phox</sup> in FLT3-ITD expressing MV4-11 cells had no effect on NOX4 67 kDa and NOX4D 28 kDa protein expression. NOX4D 28 kDa is glycosylated in FLT3-ITD expressing AML. (A)** Western blot analysis of p22<sup>phox</sup>, NOX4 67 kDa and NOX4D 28 kDa protein levels in MV4-11 whole cell lysates at 24 h following p22<sup>phox</sup> siRNA transfection. β-actin was used as a loading control. **(B)** Western blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein expression in whole cell lysates following treatment with tunicamycin (5 μg/ml) **(i)** and brefeldin A (10 μg/ml) **(ii)** overnight. (Asterisks indicate a shift in protein molecular weight). β-actin and total protein were used as loading controls. Blots are representative of three independent experiments.

**NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent of ERK1/2 signalling however p22<sup>phox</sup>-mediated H<sub>2</sub>O<sub>2</sub> production requires ERK1/2 activation**

The ERK1/2 pathway is known to be activated downstream of constitutively activated FLT3-ITD. We

investigated the effect of ERK1/2 signalling inhibition using U0126 in MV4-11 cells (Figure 5A) on NOX4D 28 kDa protein expression. Inhibition of ERK1/2 signalling did not cause a decrease in NOX4 67 kDa and NOX4D 28 kDa protein expression when compared to control, however, p22<sup>phox</sup> protein expression decreased following treatment with 50 μM and 100 μM U0126 (Figure 5B).




**Figure 3: Inhibition of the FLT3 receptor in 32D/FLT3-ITD cells and FLT3-ITD expressing MV4-11 cells reduces NOX4 67 kDa and NOX4D 28 kDa protein expression and total endogenous H<sub>2</sub>O<sub>2</sub>.** Inhibition of the FLT3 receptor following treatment with PKC412, results in a decrease in total endogenous H<sub>2</sub>O<sub>2</sub> in 32D/FLT3-ITD cells but not in 32D/FLT3-WT cells. (A) 32D/FLT3-WT and 32D/FLT3-ITD cells were IL-3 starved overnight and treated for 24 h with PKC412 (50 nM and 200 nM), followed by staining with H<sub>2</sub>O<sub>2</sub> specific probe PO1 for 1 h before FACS reading. Bar charts show relative mean PO1 fluorescence of treated cells expressed as % of control. The results are representative of four independent experiments. Asterisks indicate statistically significant differences (\*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars represent SD. (B) Western blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein expression in MV4-11 whole cell lysates following treatment with PKC412 for 24 h at indicated concentrations. β-actin was used as a loading control. Blots are representative of three independent experiments. (C) (i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with PKC412 for 24 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate statistically significant differences (\*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars represent SD. (D and E) Western blot analysis of NOX4D 28 kDa protein expression in the nuclear fraction following treatment with AC220 (10 nM, 20 nM and 30 nM) for 12 h in MV4-11 cells (D) and 32D cells transfected with FLT3-ITD (E). Equal loading of nuclear fractions was demonstrated by probing for nuclear-localised Lamin A/C. Blots are representative of three independent experiments.

This suggests that NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent of ERK1/2 signalling. A decrease of 40-45% in total endogenous H<sub>2</sub>O<sub>2</sub> was observed following treatment with 50 μM and 100 μM U0126 (Figure 5C).

### NOX4 67 kDa and NOX4D 28 kDa generate pro-survival ROS downstream of STAT5 signalling

Previous studies have shown that FLT3-ITD drives evident activation of STAT5 signalling compared




**Figure 4: NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS require AKT activation.** (A) Western blot analysis of AKT signalling in FLT3-ITD expressing MV4-11 cells following treatment with LY294002 (20 μM, 30 μM and 50 μM) for 16 h. β-actin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with LY294002 for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of three independent experiments. (C) (i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with LY294002 for 16 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate statistically significant differences (\*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars are representative of SD.



to FLT3-WT resulting in increased mRNA and protein expression of NOX4 [27, 47, 48]. Given that treatment with pimozide clearly reduced NOX4 mRNA in FLT3-


ITD expressing MV4-11 cells [27], we investigated the effect of STAT5 inhibition in MV4-11 cells (Figure 6A) on NOX4D 28 kDa protein expression. Treatment



**Figure 5: NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent of ERK1/2 signalling. p22<sup>phox</sup> generated H<sub>2</sub>O<sub>2</sub> requires ERK1/2 activation.** (A) Western blot analysis of ERK1/2 signalling in FLT3-ITD expressing MV4-11 cells following treatment with U0126 (10  $\mu$ M, 20  $\mu$ M, 50  $\mu$ M and 100  $\mu$ M) for 16 h.  $\alpha$ -tubulin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with U0126 for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions was assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of three independent experiments. (C) (i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with U0126 for 16 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of four independent experiments. Asterisks indicate statistically significant differences (\*p<0.05, \*\*\*p<0.001, \*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars are representative of SD.

with indicated concentrations of pimoziide resulted in a pronounced decrease in NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression following treatment with 20  $\mu$ M pimoziide (Figure 6B). Furthermore, inhibition of

STAT5 signalling caused a decrease of 30-40% in total endogenous H<sub>2</sub>O<sub>2</sub> at all concentrations (Figure 6C), indicating a role for STAT5 signalling in the production of NOX4D-generated pro-survival ROS.



**Figure 6: NOX4 67 kDa and NOX4D 28 kDa generate H<sub>2</sub>O<sub>2</sub> downstream of STAT5 activation.** (A) Western blot analysis of STAT5 signalling in FLT3-ITD expressing MV4-11 cells following treatment with pimoziide (5  $\mu$ M, 10  $\mu$ M and 20  $\mu$ M) for 16 h.  $\beta$ -actin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with pimoziide for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of four independent experiments. (C)(i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with pimoziide for 16 h at indicated concentrations. (ii) Bar chart shows mean relative PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate statistically significant differences (\*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars are representative of SD.

## Inhibition of GSK3 $\beta$ signalling in MV4-11 cell line increases NOX4 67 kDa and NOX4D 28 kDa protein levels and decreases p22<sup>phox</sup> protein levels

Previous studies in our laboratory have demonstrated that PKC412-mediated p22<sup>phox</sup> down-regulation requires GSK3 $\beta$  activation, establishing a role for GSK3 $\beta$  signalling in post-translational regulation of NOX4 partner protein p22<sup>phox</sup> [22]. SB216763, a drug described as an inhibitor of GSK3 $\beta$  [49, 50] was found to decrease pGSK3 $\beta$  (Ser 9) protein levels significantly in MV4-11 cells, therefore resulting in the activation of GSK3 $\beta$  signalling (Figure 7A). Treatment of MV4-11 cells with indicated concentrations of SB216763 showed no obvious effect on NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein levels in membrane and soluble nuclear fractions (Figure 7B). However, activation of GSK3 $\beta$  signalling increased total endogenous H<sub>2</sub>O<sub>2</sub> by 45-50% following treatment with 1  $\mu$ M and 2  $\mu$ M SB216763 and ~40% following treatment with 5  $\mu$ M SB216763 (Figure 7C). Lithium chloride (LiCl) is widely used as a GSK3 $\beta$  inhibitor [51]. Inhibition of GSK3 $\beta$  using LiCl caused an increase in pGSK3 $\beta$  (Ser 9) protein levels (Figure 7D) in MV4-11 cells, indicative of inhibition of the pathway. This increase coincided with an increase in NOX4 67 kDa and NOX4D 28 kDa proteins in membrane and soluble nuclear fractions. Interestingly, p22<sup>phox</sup> protein levels decreased following treatment with 50 mM LiCl in both membrane and soluble nuclear fractions (Figure 7E). Inhibition of GSK3 $\beta$  activation had little or no effect on total endogenous H<sub>2</sub>O<sub>2</sub> levels (Figure 7F).

## DISCUSSION

FLT3-ITD is the most prevalent mutation in AML accounting for 20-30% of patient cases [5, 7, 8] and has been associated with an aggressive phenotype [11-13]. NOX-derived ROS have been shown to have numerous roles in leukaemia including cell survival, cell proliferation and a differentiation block [52, 53]. Leukaemic oncogenes have been widely documented in the regulation of NOX proteins and their partner protein p22<sup>phox</sup> [8, 54]. Our group has shown that 32D cells transfected with FLT3-ITD possess higher NOX4 and p22<sup>phox</sup> levels than their wild type counterpart contributing to genomic instability in FLT3-ITD expressing AML. Furthermore, 32D/FLT3-ITD cells exhibit higher levels of total endogenous and nuclear H<sub>2</sub>O<sub>2</sub> and DNA damage than 32D/FLT3-WT cells [23].


Unlike other NOX family members, NOX4 is constitutively activated. Subcellular localisation of NOX4 is key to its role in ROS production and genetic instability. NOX4 has been reported to be expressed in the nucleus [55-62] amongst other previously identified locations including the cytoskeleton [35], ER [30, 36-38], mitochondria [39, 40] and plasma membrane [38,

41]. Our laboratory has previously shown that NOX4 and p22<sup>phox</sup> co-localise to the nuclear membrane of FLT3-ITD expressing MV4-11 cells [23]. Previous studies have identified the presence of NOX4 isoforms or splice variants [45]. NOX4D 28 kDa is of particular interest, as it is found in the nucleus and nucleolus of multiple cell types including human aortic smooth muscle cells, HUVECs, H9C2 rat cardiomyocyte cells, HEK cells, mouse primary cardiac fibroblasts and rat neonatal cardiomyocytes where it contributes to ROS production and DNA damage [42].

In this study, we investigated the expression, localisation and regulation of NOX4D-generated pro-survival ROS in FLT3-ITD expressing AML. We found that FLT3-ITD expressing AML patient samples and cells possess the NOX4D splice variant. FLT3-ITD expressing AML cells express NOX4D in the membrane and soluble nuclear fractions. NOX4D was not detected in the FLT3-WT expressing patient samples and cells, suggesting a role for nuclear membrane-localised NOX4D 28 kDa in the generation of pro-survival ROS in FLT3-ITD expressing AML. In line with previous work, we detected NOX4 67 kDa in the soluble nuclear fraction and its partner protein p22<sup>phox</sup> in the membrane and soluble nuclear fractions of MV4-11 and 32D/FLT3-ITD cells (Figure 1). 32D cells stably transfected with FLT3-ITD express NOX4D 28 kDa and possess elevated levels of total endogenous H<sub>2</sub>O<sub>2</sub> compared to their wild-type counterpart. Importantly, to our knowledge, this is the first study to identify the role of nuclear membrane-localised NOX4D 28 kDa in pro-survival ROS production and genomic instability in FLT3-ITD expressing AML cells (Figure 1).

p22<sup>phox</sup> is a partner protein of NOX1-4 and is required for NOX4 activation [30]. We found that p22<sup>phox</sup> knockdown had no significant effect on NOX4 67 kDa and NOX4D 28 kDa protein levels (Figure 2). Interestingly, previous studies have shown that NOX4 knockdown resulted in depletion of p22<sup>phox</sup> protein levels in HUVECs with no change in p22<sup>phox</sup> mRNA expression [43]. This suggests that the formation of NOX4 and p22<sup>phox</sup> complex in the nucleus of HUVECs is responsible for the stabilisation of p22<sup>phox</sup> at the protein level.

Recent studies in our laboratory have revealed that NOX4 67 kDa is glycosylated in FLT3-ITD expressing MV4-11 cells [28]. We show that NOX4D 28 kDa is also glycosylated in MV4-11 cells, by using a glycosylation inhibitor, tunicamycin, and a receptor trafficking inhibitor, brefeldin A. By inhibiting glycosylation, NOX4D 28 kDa was observed at a lower molecular weight (Figure 2). Indeed, NOX4D 28 kDa is glycosylated in A549 cells [45]. We have shown that deglycosylation of NOX4 67 kDa [28] and now NOX4D 28 kDa (Figure 2) coincides with significant decreases in total endogenous H<sub>2</sub>O<sub>2</sub> [28]. This suggests that the glycosylation of NOX4 67 kDa and NOX4D 28 kDa may be important for their role in the production of pro-survival ROS and DNA damage in AML. Tunicamycin and brefeldin A have recently been shown to inhibit receptor trafficking of the FLT3-




**Figure 7: Inhibition of GSK3 $\beta$  signalling results in elevated NOX4 67 kDa and NOX4D 28 kDa protein expression.** (A) Western blot analysis of GSK3 $\beta$  signalling in FLT3-ITD expressing MV4-11 cells following treatment with SB216763 (1  $\mu$ M, 2  $\mu$ M and 5  $\mu$ M) for 16 h.  $\beta$ -actin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with SB216763 for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of four independent experiments. (C)(i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with SB216763 for 16 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate statistically significant differences (\*\*\*p<0.001, \*\*\*\*p<0.0001) as analysed by Student's t-test. Error bars are representative of SD. (D) Western blot analysis of GSK3 $\beta$  signalling in FLT3-ITD expressing MV4-11 cells following treatment with lithium chloride (10 mM, 20 mM and 50 mM) for 16 h.  $\beta$ -actin and total protein were used as loading controls. (E) NOX4 67 kDa, NOX4D 28 kDa and p22<sup>phox</sup> protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with lithium chloride for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of three independent experiments. (F)(i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with lithium chloride for 16 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of four independent experiments. Asterisks indicate statistically significant differences (\*\*p<0.01, \*\*\*p<0.001) as analysed by Student's t-test. Error bars are representative of SD.

ITD receptor to the plasma membrane which caused inactivation of both the AKT and ERK1/2 pathways [16, 28]. Although tunicamycin and brefeldin A inhibit many glycosylated proteins, mild inhibition of glycosylation using tunicamycin in combination with FLT3 kinase inhibitors has shown therapeutic potential for the treatment of FLT3-ITD expressing AML [63].

We have previously demonstrated that FLT3-ITD is involved in the up-regulation of NOX4 both at mRNA and protein levels [23, 27]. Inhibition of FLT3-ITD activity using several FLT3 receptor inhibitors including AC220, AG1295 and PKC412 caused a decrease in NOX4 mRNA and protein expression [27, 28] presenting a role for FLT3-ITD in NOX4-generated ROS production in AML. Here, we have shown that FLT3-ITD patient samples and cells express the NOX4D 28 kDa splice variant alongside a dramatic increase in total endogenous  $H_2O_2$  compared to their wild-type counterpart that do not express NOX4D (Figure 1). Inhibition of the FLT3 receptor using PKC412

caused a decrease in total endogenous  $H_2O_2$  in 32D/FLT3-ITD cells compared to 32D/FLT3-WT cells (Figure 3). FLT3-ITD inhibition in MV4-11 cells treated with PKC412 resulted in down-regulation of NOX4 67 kDa and NOX4D 28 kDa protein expression alongside a decrease in  $H_2O_2$  levels (Figure 3). Treatment of MV4-11 and 32D/FLT3-ITD cells with FLT3 receptor inhibitor AC220 also led to decreased expression of NOX4D 28 kDa. PKC412 (midostaurin) has recently been approved by the FDA and AC220 is currently being tested in clinical trials for the treatment of AML [64-66]. Previous studies has shown that FLT3-ITD inhibition using PKC412 and NOX inhibition via diphenyleneiodonium (DPI) in 32D/FLT3-ITD cells resulted in ~25-40% decrease in  $\gamma$ H2AX levels, a marker of dsbs [23]. Together these findings suggest that the FLT3-ITD oncogene is responsible for the regulation and production of nuclear membrane-localised NOX4D-generated  $H_2O_2$  in AML contributing to genetic instability and an aggressive phenotype.



**Figure 8: A schematic of the proposed mechanism of FLT3-ITD-driven NOX4D-generated  $H_2O_2$  in AML.** GSK3 $\beta$ , ERK1/2, PI3K/AKT and STAT5 pro-survival pathways are located downstream of FLT3-ITD. Activation of AKT and STAT5 signalling by the FLT3-ITD oncogene results in the activation and production of DNA damaging NOX4D-generated  $H_2O_2$  at the nuclear membrane.

Three major pro-survival pathways are activated downstream of FLT3-ITD in AML: PI3K/AKT, ERK1/2 and STAT5 pathway [10, 16]. We have shown that the PI3K/AKT pathway needs to be activated in order for NOX4 to generate its oncogenic effects in AML [27, 28]. Inhibition of the PI3K/AKT pathway revealed that the PI3K/AKT pathway is responsible for the activation and generation of NOX4-, NOX4D- and p22<sup>phox</sup> generated H<sub>2</sub>O<sub>2</sub> (Figure 4). Although the ERK1/2 pathway is located downstream of FLT3-ITD, inhibition of ERK1/2 signalling was found to have no noticeable effects on NOX4- and NOX4D- protein expression. However, inactivation of ERK1/2 signalling revealed that ERK1/2 activation is involved in the stimulation and production of p22<sup>phox</sup>-mediated H<sub>2</sub>O<sub>2</sub> production in AML (Figure 5). p22<sup>phox</sup> is a partner protein of NOX1, NOX2 and NOX3 as well as NOX4, all of which have a role in ROS production. We have previously demonstrated that NOX2 is also involved in ROS production and DNA damage contributing to genetic instability in FLT3-ITD expressing AML. This same study confirmed that NOX1 does not contribute significantly to ROS production or dsbs [23]. Patient derived FLT3-expressing myeloid cells have been shown to express NOX2, NOX4 and NOX5. However, their murine counterpart have been shown to express NOX1, NOX2 and NOX4. These cells did not express NOX3 [53]. Therefore it is likely that ERK1/2 activation is involved in the production of NOX2-generated H<sub>2</sub>O<sub>2</sub> in FLT3-ITD expressing AML. Recent findings have identified STAT5 signalling downstream of FLT3-ITD and its requirement for the up-regulation of NOX4-generated H<sub>2</sub>O<sub>2</sub> alongside the inactivation of DEP-1 PTP a negative regulator of FLT3 signalling activity [27]. Inhibition of STAT5 signalling revealed that activated STAT5 is required for the production of NOX4-, NOX4D- and p22<sup>phox</sup>-generated ROS (Figure 6). This suggests that NOX4D may also have a role in the partial inactivation of DEP-1 PTP resulting in cellular transformation in FLT3-ITD expressing AML.

GSK3 $\beta$  is another pathway known to be located downstream of FLT3-ITD. Inhibition of the PI3K/AKT pathway in MV4-11 cells resulted in increased expression of pGSK3 $\beta$  (Ser 9) suggesting that the GSK3 $\beta$  pathway is not located downstream of the PI3K/AKT pathway [28]. Phosphorylation of GSK3 $\beta$  at Serine 9 decreased following ERK1/2 inhibition suggesting that the GSK3 $\beta$  pathway is located downstream of ERK1/2 (data not shown). Inhibition of FLT3-ITD signalling caused a decrease in phosphorylation of GSK3 $\beta$  (Ser 9), resulting in increased GSK3 $\beta$  activation which has been shown previously to play a crucial role in the post-translational regulation of p22<sup>phox</sup> [22, 28]. SB216763 is described as an inhibitor of GSK3 $\beta$ , and GSK3 $\beta$  is inhibited when it is phosphorylated. In disagreement with this, SB216763 was found to decrease levels of pGSK3 $\beta$  in MV4-11 cells (Figure 7), suggesting that it is acting as an activator of GSK3 $\beta$ . It is possible that SB216763 could have different effects in other cell types. However, based on our

findings, we advise careful consideration and assessment of pGSK3 $\beta$  levels when using this drug. Activation of GSK3 $\beta$  was found to have no noticeable effect on NOX4-, NOX4D- and p22<sup>phox</sup> protein expression, however an increase in H<sub>2</sub>O<sub>2</sub> levels was observed (Figure 7). The activation of GSK3 $\beta$  signalling has been found to be pro-apoptotic in several systems and can provoke mitochondrial injury and this may be responsible for the increase in H<sub>2</sub>O<sub>2</sub> levels [67-69]. Lithium chloride, also described as an inhibitor of GSK3 $\beta$ , resulted in the expected increase in pGSK3 $\beta$  in MV4-11 cells, indicating inhibition (Figure 7). Inhibition of GSK3 $\beta$  signalling using LiCl revealed an increase in NOX4- and NOX4D-protein expression, however, p22<sup>phox</sup> protein levels decreased. Moreover, inhibition of GSK3 $\beta$  signalling had little or no effect on total endogenous H<sub>2</sub>O<sub>2</sub> (Figure 7).

In conclusion, we suggest that the FLT3-ITD oncogene is responsible for the activation and generation of NOX4D-generated pro-survival H<sub>2</sub>O<sub>2</sub> at the nuclear membrane contributing to DNA damage and genetic instability in AML. Glycosylation of NOX4 and NOX4D is essential for the production of pro-survival ROS. Activation of PI3K/AKT and STAT5 signalling is required in order for NOX4D to generate its oncogenic effects. These findings are summarised in Figure 8. This study emphasises the potential of NOX as an effective therapeutic target in FLT3-ITD expressing AML, as inhibition and deglycosylation of NOX4 and NOX4D can decrease the levels of H<sub>2</sub>O<sub>2</sub> and DNA damage that would otherwise contribute to genetic instability. From a clinical point of view, adaptation of tumour cells to enhanced ROS production may result in tumour cells being less responsive to the standard cytotoxic chemotherapy, which operates through severe oxidative stress. Together the data presented here and in previous studies by our laboratories identifies receptor trafficking inhibitors/glycosylation inhibitors and NOX inhibitors as potential therapies for the treatment of FLT3-ITD expressing AML which when treated in combination with standard chemotherapy may improve the effectiveness of the treatment.

## MATERIALS AND METHODS

### Primary AML patient samples

Blood samples from newly diagnosed untreated *de novo* AML patients were obtained in accordance with the Declaration of Helsinki and with approval of the institutional review board of the University Hospital Jena, Germany. Mononuclear cells were purified as previously described in [21]. FLT3 mutational analysis was done by standard PCR methods to group the patients into FLT3-WT or FLT3-ITD.

### Cell culture and treatments

The human leukaemic cell line MV4-11 (homozygous for the FLT3-ITD mutation) was purchased

from DSMZ (Braunschweig, Germany). The 32D cell lines, stably transfected with FLT3-WT and FLT3-ITD [18], were a kind gift from Prof. Hubert Serve (Goethe University Frankfurt, Germany). MV4-11 and 32D cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin in a humidified incubator at 37°C with 5% CO<sub>2</sub>. For the 32D cell lines, 10% WEHI-conditioned medium was added as a source of IL-3. HEK 293-T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% FBS, 10 mM L-glutamine and 1% penicillin/streptomycin in a humidified incubator at 37°C with 5% CO<sub>2</sub>.

FLT3-ITD was inhibited using PKC412 (50 nM, 200 nM and 250 nM; Tocris) for up to 24 h and AC220 (10nM, 20nM, and 30nM; generous gift of Dr. Siavosh Mahboobi (University of Regensburg, Germany)) for 12 h. Glycosylation was inhibited using tunicamycin (5 µg/ml; Sigma) and brefeldin A (10 µg/ml; Sigma) overnight. Inhibition of PI3K/AKT was achieved via treatment with LY294002 (20 µM, 30 µM and 50 µM; Cell Signaling) for 16 h; inhibition of ERK1/2 via U0126 (10 µM, 20 µM, 50 µM and 100 µM; Sigma) for 16 h; inhibition of STAT5 via pimozide (5 µM, 10 µM and 20 µM; Merck Millipore) for 16 h; modulation of GSK3β via SB216763 (1 µM, 2 µM and 5 µM; Tocris); inhibition of GSK3β via Lithium chloride (LiCl) (10 mM, 20 mM and 50 mM; Sigma) for 16 h. Vehicle controls used were dimethylsulfoxide (DMSO; for all drugs unless otherwise stated), sterile water (for LiCl) and Ethanol (for brefeldin A).

## Antibodies

Primary antibodies used for immunoblotting included NOX4 (Ab109225; Abcam; used for human primary AML samples), NOX4 (NB110-58849; Novus Biologicals; used for all other analyses), p22<sup>phox</sup> (#SC20781; Santa Cruz Biotechnology), β-Actin (A5441), α-Tubulin (T5168) (Sigma), Vinculin (BZL03106; Biozol), NUP98 (Ab179911 (13C1)), Histone H3 (Ab1220), Calreticulin (Ab22683), KDEL (Ab12223) (Abcam), GAPDH (#5174), Lamin A/C (#2032), HDAC1 (#5356), pAKT (Ser473; #9271), AKT(#9272), pERK1/2 (Thr202/Tyr204; #9106), ERK1/2 (#4696), pGSK3β (Ser9; #9336), GSK3β (#9315) (Cell Signaling), pSTAT5 (Tyr694/699; #04-886; Millipore), STAT5 (#610191; BD Biosciences) and HA (#MMS-101R; Cambridge Bioscience).

## Western blotting

The immunoblotting procedure was carried out as previously described [22]. Briefly, whole cells were lysed in radio-immunoprecipitation assay (RIPA) buffer [Tris-HCl (50mM; pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, NaCl (150mM), EGTA (1mM), sodium orthovanadate (1mM), sodium fluoride (1mM), cocktail

protease inhibitors (Roche, Welwyn, Hertfordshire, UK) and phenylmethanesulfonyl fluoride (1mM)] for 35-45 minutes at 4°C in a vortex, followed by centrifugation at 14,000 rpm for 15 min to remove cell debris. Subcellular fractionation was performed to detect the expression and localisation of the NOX4 28kDa isoform (NOX4D) using a subcellular fractionation kit (Thermo Scientific, Waltham, MA USA), according to the manufacturer's instructions. The protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK). In all cases equivalent amounts of protein, were resolved using SDS-PAGE in 4X Protein Sample Loading Buffer (LI-COR, cat# P/N 928-40004) followed by transfer to nitrocellulose membrane (Schleicher and Schuell, Whatman, Dassel, Germany). Total protein levels were analysed using REVERT total protein stain (LI-COR, cat# P/N 926-11011) as per manufacturer's instructions and imaged on a LI-COR Odyssey infrared imaging system (LI-COR Biosciences UK Ltd, Cambridge, UK). The membranes were blocked for 1 h and incubated overnight with primary antibodies. The membranes were incubated in secondary antibody coupled with Alexa Fluor 680 or 800. Antibody reactive bands were detected using a LI-COR Odyssey infrared imaging system.

## Small interfering RNA (siRNA) and small hairpin RNA (shRNA)

siRNA transfection of MV4-11 cells was performed using the Nucleofector kit L (Amaxa, Cologne, Germany) and Amaxa Nucleofector Technology (Q-001 program) according to the company's protocol. The predesigned siRNA used for p22<sup>phox</sup> siRNA was A: s201230. The sequences are available from the manufacturer's website. For the negative control, the siRNA used was Silencer Select Negative Control #1 siRNA. All were purchased from Ambion, Warrington, UK. NOX4 siRNA and shRNA in 32D/FLT3-ITD cells were carried out as previously described [27].

## Measurement of intracellular H<sub>2</sub>O<sub>2</sub>

Measurement of intracellular H<sub>2</sub>O<sub>2</sub> was performed as previously described in [28]. Briefly, following treatments, total intracellular H<sub>2</sub>O<sub>2</sub> was measured by incubating cells with 5 µM of cell-permeable H<sub>2</sub>O<sub>2</sub>-probe PO1 (Tocris) for 1 h at 37°C in the dark. Cells were quantified by flow cytometry using FACSCalibur (BD Biosciences, Europe) and Cellquest Pro software (Becton Dickinson). The mean fluorescent intensity of 10,000 events was determined.

## NOX4 overexpression transfections

For NOX4 overexpression in HEK 293-T cells, cells were transfected using Calcium Phosphate. Briefly, cells were seeded 5 h prior to transfection to allow confluency

of 70%. 4 µg of pCMV3-C-HA encoding NOX4 (#HG15189-CY; Sino Biological, UK) was added to CaCl<sub>2</sub>. The DNA/CaCl<sub>2</sub> mixture was then added dropwise to 2X HBSS at a ratio of 1:1. Samples were allowed to stand for 1-2 min after which the solution was distributed to the pre-seeded cells in a dropwise manner. Cells were then incubated overnight to allow the transfection to proceed, after which cells were reseeded for experimental purposes and lysed 48 h later.

### Statistical analysis

The results are expressed as a percentage of control, set to 100%. Values are representative of mean ± SD and are representative of three or more independent experiments. Statistical significance was analyzed by Student's t-test (GraphPad Prism 6 software) with p<0.05 representing a significant result.

### Abbreviations

AML, acute myeloid leukaemia; chr.b.nuclear, chromatin bound nuclear; DMSO, dimethylsulfoxide; DPI, Diphenyleneiodonium; dsbs, double strand breaks; DUOX, dual oxidase; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinases; EV, empty vector; FAD, Flavin adenine dinucleotide; FLT3, FMS-like tyrosine kinase 3; FLT3-ITD, FLT3-internal tandem duplication; FLT3-WT, FLT3-wild-type; GSK3β, glycogen synthase kinase-3 β; HEK, human embryonic kidney; HUVEC, human umbilical vein endothelium cells; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxidase; LiCl, Lithium chloride; NOX, nicotinamide adenine dinucleotide phosphate oxidase; p22<sup>phox</sup>, p22 phagocyte oxidase; PI3K, phosphoinositide 3 kinase; PO1, peroxy orange 1; PTP, protein tyrosine phosphatase; RIPA, radio-immunoprecipitation assay; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; STAT5, signal transducer and activator of transcription 5; VSMC, vascular smooth muscle cells.

### Author contributions

*Conceptualisation:* J.N.M. T.G.C.

*Funding acquisition:* F.D.B. T.G.C.

*Investigation:* J.N.M. A.K.J. J.S. S.L.R. R.L.O'B.

*Resources:* S.S.

*Writing- original draft:* J.N.M. T.G.C.

*Writing- review and editing:* J.N.M. A.K.J. J.S. S.L.R. F.D.B. T.G.C.

### ACKNOWLEDGMENTS AND FUNDING

The authors would like to thank Dr Alice Wyse-Jackson, Ms Ana Ruiz-Lopez and Dr Ashleigh Byrne for their guidance, discussion and critical analysis of the work.

This work was supported by the Children's Leukaemia Research Project Ireland (T.G.C. and J.N.M.), the Deutsche Forschungsgemeinschaft (DFG BO 1043/10-2) (F.D.B. and A.K.J.) and the German Academic Exchange Service (DAAD) (A.K.J.). In particular we would like to extend a special thanks to Tommy Monahan and his team at the Children's Leukaemia Research Project.

### CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

### REFERENCES

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. *Nature*. 2001; 411:355-65. <https://doi.org/10.1038/35077225>.
2. Köthe S, Müller JP, Böhmer SA, Tschongov T, Fricke M, Koch S, Thiede C, Requardt RP, Rubio I, Böhmer FD. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells. *Journal of Cell Science*. 2013; 126:4746-55. <https://doi.org/10.1242/jcs.131789>.
3. Regad T. Targeting RTK signaling pathways in cancer. *Cancers*. 2015; 7:1758-84. <https://doi.org/10.3390/cancers7030860>.
4. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. *Nat Rev Cancer*. 2003; 3:650-65. <https://doi.org/10.1038/nrc1169>.
5. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. *Blood*. 2002; 100:1532-42. <https://doi.org/10.1182/blood-2002-02-0492>.
6. Wang A, Wu H, Chen C, Hu C, Qi Z, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. *Oncotarget*. 2016; 7:29131-42. <https://doi.org/10.18632/oncotarget.8675>.
7. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *New England Journal of Medicine*. 2013; 368:2059-74. <https://doi.org/10.1056/NEJMoa1301689>.
8. Jayavelu AK, Moloney JN, Böhmer FD, Cotter TG. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML. *Experimental Hematology*. 2016; 44:1113-22. <https://doi.org/10.1016/j.exphem.2016.08.008>.
9. Kazi JU, Rupar K, Marhäll A, Moharram SA, Khanum F, Shah K, Gazi M, Nagaraj SRM, Sun J, Chougule RA, Rönstrand L. ABL2 suppresses FLT3-ITD-induced cell



- proliferation through negative regulation of AKT signaling. *Oncotarget*. 2017; 8:12194-202. <https://doi.org/10.18632/oncotarget.14577>.
10. Nguyen B, Williams AB, Young DJ, Ma H, Li L, Levis M, Brown P, Small D. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. *Oncotarget*. 2017; 8:10931-44. <https://doi.org/10.18632/oncotarget.14539>.
  11. Small D. Targeting FLT3 for treatment of leukemia. *Seminars in hematology*. 2008; 45:S17-S21. <https://doi.org/10.1053/j.seminhematol.2008.07.007>.
  12. König H, Levis M. Targeting FLT3 to treat leukemia. *Expert opinion on therapeutic targets*. 2015; 19:37-54. <https://doi.org/10.1517/14728222.2014.960843>.
  13. De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. *Blood Cancer Journal*. 2016; 6:e441. <https://doi.org/10.1038/bcj.2016.50>.
  14. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H. Constitutive activation of Akt by Flt3 Internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. *Cancer Research*. 2005; 65:9643-50. <https://doi.org/10.1158/0008-5472.can-05-0422>.
  15. Choudhary C, Müller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic Flt3. *International Journal of Hematology*. 2005; 82:93. <https://doi.org/10.1532/ijh97.05090>.
  16. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, Böhmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Müller-Tidow C, Mann M, Serve H. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. *Molecular Cell*. 2009; 36:326-39. <https://doi.org/10.1016/j.molcel.2009.09.019>.
  17. Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, Böhmer FD, Berdel WE, Müller-Tidow C, Serve H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. *Blood*. 2007; 110:370-4. <https://doi.org/10.1182/blood-2006-05-024018>.
  18. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. *Blood*. 2000; 96:3907-14.
  19. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. *Oncogene*. 2000; 19:624-31. <https://doi.org/10.1038/sj.onc.1203354>.
  20. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. *Blood*. 2008; 111:3173-82. <https://doi.org/10.1182/blood-2007-05-092510>.
  21. Godfrey R, Arora D, Bauer R, Stopp S, Müller JP, Heinrich T, Böhmer SA, Dagnell M, Schnetzke U, Scholl S, Östman A, Böhmer FD. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ. *Blood*. 2012; 119:4499-511. <https://doi.org/10.1182/blood-2011-02-336446>.
  22. Woolley JF, Naughton R, Stanicka J, Gough DR, Bhatt L, Dickinson BC, Chang CJ, Cotter TG. H2O2 Production Downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling. *PLoS One*. 2012; 7:e34050. <https://doi.org/10.1371/journal.pone.0034050>.
  23. Stanicka J, Russell EG, Woolley JF, Cotter TG. NADPH Oxidase-generated Hydrogen Peroxide Induces DNA damage in mutant FLT3-expressing leukemia cells. *The Journal of Biological Chemistry*. 2015; 290:9348-61. <https://doi.org/10.1074/jbc.M113.510495>.
  24. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, Reboul M, Lea N, Chomienne C, Thomas NSB, Mufti GJ, Padua RA. Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia? *Cancer Research*. 2007; 67:8762-71. <https://doi.org/10.1158/0008-5472.can-06-4807>.
  25. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? *Blood*. 2011; 117:5816-26. <https://doi.org/10.1182/blood-2011-01-326025>.
  26. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiological Reviews*. 2007; 87:245-313. <https://doi.org/10.1152/physrev.00044.2005>.
  27. Jayavelu A, Müller J, Bauer R, Böhmer S, Lässig J, Cerny-Reiterer S, Sperr W, Valent P, Maurer B, Moriggl R. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. *Leukemia*. 2016; 30:473-83. <https://doi.org/10.1038/leu.2015.234>.
  28. Moloney JN, Stanicka J, Cotter TG. Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia. *Leukemia Research*. 2017; 52:34-42. <https://doi.org/10.1016/j.leukres.2016.11.006>.
  29. Brandes RP, Weissmann N, Schröder K. Nox family NADPH oxidases: molecular mechanisms of activation. *Free Radical Biology and Medicine*. 2014; 76:208-26. <https://doi.org/10.1016/j.freeradbiomed.2014.07.046>.
  30. Ambasta RK, Kumar P, Griendling KK, Schmidt HHHW, Busse R, Brandes RP. Direct interaction of the novel nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. *Journal of Biological Chemistry*. 2004; 279:45935-41. <https://doi.org/10.1074/jbc.M406486200>.

31. Moloney JN, Cotter TG. ROS signalling in the biology of cancer. *Seminars in Cell & Developmental Biology*. 2017. <https://doi.org/10.1016/j.semcdb.2017.05.023>.
32. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. *Cellular Signalling*. 2006; 18:69-82. <https://doi.org/10.1016/j.cellsig.2005.03.023>.
33. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. *The Biochemical Journal*. 2007; 406:105-14. <https://doi.org/10.1042/BJ20061903>.
34. Takac I, Schröder K, Zhang L, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, Brandes RP. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. *Journal of Biological Chemistry*. 2011; 286:13304-13. <https://doi.org/10.1074/jbc.M110.192138>.
35. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2004; 24:677-83. <https://doi.org/10.1161/01.ATV.0000112024.13727.2c>.
36. Chen K, Kirber MT, Xiao H, Yang Y, Keaney JF. Regulation of ROS signal transduction by NADPH oxidase 4 localization. *The Journal of Cell Biology*. 2008; 181:1129-39. <https://doi.org/10.1083/jcb.200709049>.
37. Helmcke I, Heumüller S, Tikkanen R, Schröder K, Brandes RP. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. *Antioxidants & redox signaling*. 2009; 11:1279-87. <https://doi.org/10.1089/ARS.2008.2383>.
38. Zhang L, Nguyen MVC, Lardy B, Jesaitis AJ, Grichine A, Rousset F, Talbot M, Paquet MH, Qian G, Morel F. New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4. *Biochimie*. 2011; 93:457-68. <https://doi.org/10.1016/j.biochi.2010.11.001>.
39. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:14385-90. <https://doi.org/10.1073/pnas.0906805106>.
40. Case AJ, Li S, Basu U, Tian J, Zimmerman MC. Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons. *American Journal of Physiology - Heart and Circulatory Physiology*. 2013; 305:H19-H28. <https://doi.org/10.1152/ajpheart.00974.2012>.
41. Lee YM, Kim BJ, Chun YS, So I, Choi H, Kim MS, Park JW. NOX4 as an oxygen sensor to regulate TASK-1 activity. *Cellular Signalling*. 2006; 18:499-507. <https://doi.org/10.1016/j.cellsig.2005.05.025>.
42. Anilkumar N, San Jose G, Sawyer I, Santos CX, Sand C, Brewer AC, Warren D, Shah AM. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells significance. *Arteriosclerosis, thrombosis, and vascular biology*. 2013; 33:e104-e12. <https://doi.org/10.1161/ATVBAHA.112.300956>.
43. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh-Ohmi S, Igarashi K, Shibata Y, Sueishi K, Sumimoto H. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. *Genes to Cells*. 2005; 10:1139-51. <https://doi.org/10.1111/j.1365-2443.2005.00907.x>.
44. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie LH, Tian B, Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. *Circulation research*. 2013; 112:651-63. <https://doi.org/10.1161/CIRCRESAHA.112.279760>.
45. Goyal P, Weissmann N, Rose F, Grimminger F, Schäfers HJ, Seeger W, Hänze J. Identification of novel Nox4 splice variants with impact on ROS levels in A549 cells. *Biochemical and Biophysical Research Communications*. 2005; 329:32-9. <https://doi.org/10.1016/j.bbrc.2005.01.089>.
46. Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD. Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain. *Biochemistry*. 2010; 49:2433-42. <https://doi.org/10.1021/bi9022285>.
47. Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. *Blood*. 2005; 106:265-73. <https://doi.org/10.1182/blood-2004-07-2942>.
48. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. *Blood*. 2005; 105:4792-9. <https://doi.org/10.1182/blood-2004-11-4430>.
49. Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S. Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. *PLoS One*. 2011; 6:e24648. <https://doi.org/10.1371/journal.pone.0024648>.
50. Tao L, Fan F, Liu Y, Li W, Zhang L, Ruan J, Shen C, Sheng X, Zhu Z, Wang A, Chen W, Huang S, Lu Y. Concerted suppression of STAT3 and GSK3 $\beta$  is involved in growth inhibition of non-small cell lung cancer by xanthatin. *PLoS One*. 2013; 8:e81945. <https://doi.org/10.1371/journal.pone.0081945>.
51. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. *Nat Rev Drug Discov*. 2004; 3:479-87. <https://doi.org/10.1038/nrd1415>.
52. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.

- Leukemia. 2009; 23:1432-40. <https://doi.org/10.1038/leu.2009.49>.
53. Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. *Leukemia*. 2011; 25:281-9. <https://doi.org/10.1038/leu.2010.263>.
54. Landry WD, Woolley JF, Cotter TG. Imatinib and Nilotinib inhibit Bcr–Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. *Leukemia Research*. 2013; 37:183-9. <https://doi.org/10.1016/j.leukres.2012.11.003>.
55. Spencer NY, Yan Z, Boudreau RL, Zhang Y, Luo M, Li Q, Tian X, Shah AM, Davisson RL, Davidson B, Banfi B, Engelhardt JF. Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. *Journal of Biological Chemistry*. 2011; 286:8977-87. <https://doi.org/10.1074/jbc.M110.193821>.
56. Gordillo G, Fang H, Park H, Roy S. Nox-4–Dependent Nuclear H<sub>2</sub>O<sub>2</sub> Drives DNA Oxidation resulting in 8-OHdG as urinary biomarker and hemangioendothelioma formation. *Antioxidants & Redox Signaling*. 2009; 12:933-43. <https://doi.org/10.1089/ars.2009.2917>.
57. Weyemi U, Dupuy C. The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses. *Mutation Research/Reviews in Mutation Research*. 2012; 751:77-81. <https://doi.org/10.1016/j.mrrev.2012.04.002>.
58. Weyemi U, Lagente-Chevallier O, Boufraquech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, Schlumberger M, Dupuy C. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. *Oncogene*. 2012; 31:1117-29. <https://doi.org/10.1038/onc.2011.327>.
59. Guida M, Maraldi T, Resca E, Beretti F, Zavatti M, Bertoni L, La Sala GB, De Pol A. Inhibition of nuclear Nox4 activity by plumbagin: effect on proliferative capacity in human amniotic stem cells. *Oxidative Medicine and Cellular Longevity*. 2013; 2013:680816. <https://doi.org/10.1155/2013/680816>.
60. Guida M, Maraldi T, Beretti F, Follo MY, Manzoli L, De Pol A. Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes. *BioMed Research International*. 2014; 2014:456937. <https://doi.org/10.1155/2014/456937>.
61. Maraldi T, Guida M, Zavatti M, Resca E, Bertoni L, La Sala GB, De Pol A. Nuclear Nox4 role in stemness power of human amniotic fluid stem cells. *Oxidative Medicine and Cellular Longevity*. 2015; 2015:101304. <https://doi.org/10.1155/2015/101304>.
62. Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM. NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease. *Proceedings of the National Academy of Sciences*. 2015; 112:2121-6. <https://doi.org/10.1073/pnas.1418139112>.
63. Tsitsipatis D, Jayavelu AK, Muller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. *Oncotarget*. 2017; 8:26613-24. <https://doi.org/10.18632/oncotarget.15772>.
64. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. *Nature*. 2012; 485:260-3. <https://doi.org/10.1038/nature11016>.
65. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. *Leukemia*. 2012; 26:2061-8. <https://doi.org/10.1038/leu.2012.115>.
66. Midostaurin Gets FDA Nod for AML. *Cancer Discovery*. 2017. <https://doi.org/10.1158/2159-8290.cd-nb2017-072>.
67. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3 $\beta$  facilitates staurosporine- and heat shock-induced apoptosis: protection by lithium. *Journal of Biological Chemistry*. 2000; 275:7583-90. <https://doi.org/10.1074/jbc.275.11.7583>.
68. Macanas-Pirard P, Yaacob NS, Lee PC, Holder JC, Hinton RH, Kass GEN. Glycogen synthase kinase-3 mediates acetaminophen-induced apoptosis in human hepatoma cells. *Journal of Pharmacology and Experimental Therapeutics*. 2005; 313:780-9. <https://doi.org/10.1124/jpet.104.081364>.
69. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen Synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. *Molecular Cell*. 2006; 21:749-60. <https://doi.org/10.1016/j.molcel.2006.02.009>.